---
case_id: roche-accelerated-drug-discovery-target-identification
organisation: Roche/Genentech
title: Accelerated Drug Discovery and Target Identification
date_created: '2026-01-29'
date_updated: '2026-01-29'
sources:
- id: S1
  title: https://www.gene.com/media/press-releases/15010/2023-11-21/genentech-and-nvidia-...
  url: https://www.gene.com/media/press-releases/15010/2023-11-21/genentech-and-nvidia-enter-into-strategi
  raw_file: ''
  text_file: sources/text/S1.txt
  extraction_method: trafilatura
  extraction_quality: high
  is_multi_page: false
  related_urls: []
- id: S2
  title: https://www.roche.com/stories/ai-revolutionising-drug-discovery-and-transforming...
  url: https://www.roche.com/stories/ai-revolutionising-drug-discovery-and-transforming-patient-care
  raw_file: ''
  text_file: sources/text/S2.txt
  extraction_method: trafilatura
  extraction_quality: high
  is_multi_page: false
  related_urls: []
- id: S3
  title: https://www.drugpatentwatch.com/blog/the-ai-revolution-in-drug-repurposing-a-com...
  url: https://www.drugpatentwatch.com/blog/the-ai-revolution-in-drug-repurposing-a-comprehensive-pipeline-analysis-from-target-identification-to-clinical-and-commercial-validation/
  raw_file: ''
  text_file: sources/text/S3.txt
  extraction_method: trafilatura
  extraction_quality: high
  is_multi_page: false
  related_urls: []
- id: S4
  title: https://www.gobeyond.ai/ai-resources/case-studies/roche-ai-ml-drug-discovery-dev...
  url: https://www.gobeyond.ai/ai-resources/case-studies/roche-ai-ml-drug-discovery-development
  raw_file: ''
  text_file: sources/text/S4.txt
  extraction_method: trafilatura
  extraction_quality: high
  is_multi_page: false
  related_urls: []
value_claims:
- id: VC-002
  claim_title: AI platform transformation to expedite novel therapy discovery
  claim_description: Multi-year collaboration with NVIDIA transforms Genentech's generative
    AI models into next-generation AI platform, expediting discovery and delivery
    of novel therapies and medicines to people.
  source_ids:
  - S1
  source_quote: transforming its generative AI models and algorithms into a next-generation
    AI platform, expediting the discovery and delivery of novel therapies and medicines
    to people
  quote_location: Main announcement text
  ai_attribution: direct
  attribution_evidence: The platform transformation is explicitly stated to expedite
    discovery and delivery, with AI as the primary mechanism.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_creation
  mechanism:
  - innovation
  - optimization
  outcome:
  - velocity
  cognitive_depth: generative
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-003
  claim_title: Lab in a loop accelerates iterative therapy development
  claim_description: AI-powered 'lab in a loop' where experimental data feeds computational
    models to uncover patterns and make testable predictions, with results fed back
    to improve models for iterative development of better therapies.
  source_ids:
  - S1
  - S2
  source_quote: extensive experimental data feeds computational models that uncover
    patterns and make new, experimentally testable predictions. Scientists quickly
    assess these predictions in the lab
  quote_location: Description of lab in a loop collaboration
  ai_attribution: direct
  attribution_evidence: AI computational models directly generate predictions that
    are tested, creating an accelerated iterative cycle explicitly enabled by AI.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_creation
  mechanism:
  - automation
  - optimization
  outcome:
  - velocity
  cognitive_depth: predictive
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-004
  claim_title: AI improves drug development predictability and cost-effectiveness
  claim_description: AI plays invaluable role in revolutionizing drug development,
    making it more predictable and cost-effective, boosting R&D success rate over
    long term.
  source_ids:
  - S1
  source_quote: AI plays an invaluable role in revolutionizing drug development, in
    combination with people, science and technology, helping make it more predictable
    and cost-effective, boosting the success rate of R&D
  quote_location: Final paragraph of announcement
  ai_attribution: direct
  attribution_evidence: AI is explicitly stated as the mechanism making drug development
    more predictable, cost-effective, and improving success rates.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_enhancement
  mechanism:
  - optimization
  outcome:
  - cost_reduction
  - risk_avoidance
  cognitive_depth: predictive
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-005
  claim_title: AI enables selection of most promising cancer vaccine neoantigens
  claim_description: AI approaches enable selection of most promising neoantigens
    for cancer vaccines, leading to more effective treatments for individual patients.
  source_ids:
  - S2
  source_quote: By using AI approaches, we can select the most promising neoantigens
    (proteins generated by tumour-specific mutations) for cancer vaccines, hopefully
    leading to more effective treatments for individual patients
  quote_location: Impact on cancer vaccines section
  ai_attribution: direct
  attribution_evidence: AI approaches are explicitly stated as enabling the selection
    of promising neoantigens, directly contributing to treatment effectiveness.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_enhancement
  mechanism:
  - optimization
  - augmentation
  outcome:
  - experience
  cognitive_depth: predictive
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-006
  claim_title: AI enables rapid generation and testing of thousands of virtual molecular
    structures
  claim_description: AI and ML enable rapid generation and testing of virtual structures
    for thousands of new molecules and simulation of their interactions with therapeutic
    targets.
  source_ids:
  - S2
  source_quote: AI and ML also enable the rapid generation and testing of virtual
    structures for thousands of new molecules and the simulation of their interactions
    with therapeutic targets
  quote_location: Impact on cancer vaccines and beyond section
  ai_attribution: direct
  attribution_evidence: AI/ML are explicitly stated as enabling rapid generation,
    testing, and simulation capabilities that would not be possible otherwise.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_creation
  mechanism:
  - automation
  - innovation
  outcome:
  - velocity
  cognitive_depth: generative
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-007
  claim_title: AI strategies optimize antibody design and predict small-molecule activity
  claim_description: AI strategies are deployed to optimize antibody design, predict
    small-molecule activity, identify new antibiotic compounds and explore new disease
    indications for investigational therapies.
  source_ids:
  - S2
  source_quote: AI strategies are being deployed to optimise antibody design, predict
    small-molecule activity, identify new antibiotic compounds and explore new disease
    indications for investigational therapies
  quote_location: Impact on cancer vaccines and beyond section
  ai_attribution: direct
  attribution_evidence: AI strategies are explicitly stated as the mechanism for optimization,
    prediction, and identification across multiple therapeutic areas.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_enhancement
  mechanism:
  - optimization
  - augmentation
  outcome:
  - velocity
  - business_growth
  cognitive_depth: predictive
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
context_claims:
- id: CC-001
  context_type: organisational
  claim_title: Genentech is member of Roche Group
  claim_description: Genentech is a member of the Roche Group, a leading biotechnology
    company with headquarters in South San Francisco, California.
  source_ids:
  - S1
  source_quote: 'Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)'
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-002
  context_type: temporal
  claim_title: Multi-year strategic collaboration announced November 2023
  claim_description: Genentech and NVIDIA entered into multi-year strategic research
    collaboration announced on November 21, 2023.
  source_ids:
  - S1
  source_quote: Tuesday, Nov 21, 2023
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-003
  context_type: sectoral
  claim_title: Biotechnology and pharmaceutical industry
  claim_description: Genentech operates in biotechnology sector, discovering, developing,
    manufacturing and commercializing medicines for serious and life-threatening medical
    conditions.
  source_ids:
  - S1
  source_quote: Genentech is a leading biotechnology company that discovers, develops,
    manufactures and commercializes medicines to treat patients with serious and life-threatening
    medical conditions
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-004
  context_type: functional
  claim_title: Research and Development function
  claim_description: AI application focused on drug discovery and development within
    R&D function, specifically Genentech Research and Early Development (gRED).
  source_ids:
  - S1
  - S2
  source_quote: Aviv Regev, EVP and head of Genentech Research and Early Development
    (gRED)
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: '10880'
  apqc_name: Perform research and development
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-005
  context_type: strategic_intent
  claim_title: Strategic intent to accelerate drug discovery and improve success rates
  claim_description: Strategic goal to significantly enhance AI research programs,
    speed drug discovery, improve R&D success rates, and deliver treatments faster
    to transform patient lives.
  source_ids:
  - S1
  - S2
  source_quote: designed to significantly enhance Genentech's advanced AI research
    programs by transforming its generative AI models and algorithms into a next-generation
    AI platform
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-006
  context_type: scale
  claim_title: Large-scale biological and molecular datasets
  claim_description: Genentech possesses extensive biological and molecular datasets
    used to train AI models, combined with research expertise and experimental capabilities.
  source_ids:
  - S1
  - S2
  source_quote: Genentech's artificial intelligence (AI) capabilities, extensive biological
    and molecular datasets, and research expertise
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-007
  context_type: organisational
  claim_title: Partnership with NVIDIA for AI computing infrastructure
  claim_description: Collaboration leverages NVIDIA DGX Cloud for training-as-a-service
    platform with dedicated AI supercomputing, including NVIDIA BioNemo for generative
    AI in drug discovery.
  source_ids:
  - S1
  source_quote: accelerate and optimize Genentech's proprietary machine learning (ML)
    algorithms and models on NVIDIA DGX Cloud, which provides a training-as-a-service
    platform built on dedicated NVIDIA AI supercomputing
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-008
  context_type: organisational
  claim_title: Collaboration with AWS for computing capabilities
  claim_description: Roche collaborates with leading technology companies including
    AWS and NVIDIA to address computing capability requirements for AI in drug discovery.
  source_ids:
  - S2
  source_quote: Roche is collaborating with leading technology companies like AWS
    and NVIDIA
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-009
  context_type: products_services
  claim_title: Multiple therapeutic modalities and research areas
  claim_description: 'AI/ML foundational models applied across numerous research areas
    including diverse therapeutic modalities: cancer vaccines, antibody design, small
    molecules, antibiotics, and disease indication exploration.'
  source_ids:
  - S1
  - S2
  source_quote: developing and leveraging AI and ML foundational models across numerous
    research areas including diverse therapeutic modalities
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-010
  context_type: sectoral
  claim_title: 'Industry context: high drug development failure rates'
  claim_description: Drug discovery context characterized by lengthy, complicated,
    uncertain process with difficult-to-predict targets and approximately 90% failure
    rate in preclinical or clinical trials.
  source_ids:
  - S1
  - S2
  source_quote: Drug discovery and development is currently a lengthy, complicated,
    and uncertain process. Targets for novel medicines are difficult to predict
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-011
  context_type: temporal
  claim_title: Genentech founded over 45 years ago
  claim_description: Genentech was founded more than 45 years ago as a biotechnology
    company.
  source_ids:
  - S1
  source_quote: Founded more than 45 years ago, Genentech is a leading biotechnology
    company
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-012
  context_type: functional
  claim_title: Computational Sciences function established
  claim_description: Genentech has established Computational Sciences function led
    by Senior Vice President, bringing together cross-disciplinary expertise for AI
    applications.
  source_ids:
  - S2
  source_quote: John Marioni, Senior Vice President and Head of Computational Sciences
    at Genentech
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: '10880'
  apqc_name: Perform research and development
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
verification_summary:
  value_claims:
    total: 6
    verified: 6
    needs_review: 0
    rejected: 0
    by_attribution:
      direct: 6
  context_claims:
    total: 12
    verified: 12
    unverified: 0
    inferred: 0
  all_value_verified: true
  all_context_verified: true
human_validation_summary: null
status: complete
confidence: high
review_flags: []
ontology_metadata:
  version_used: '1.0'
  tagged_date: '2026-01-29'
  needs_retagging: false
---

# Accelerated Drug Discovery and Target Identification

## Executive Summary

Roche/Genentech: AI platform transformation to expedite novel therapy discovery.

## Key Findings

- **AI platform transformation to expedite novel therapy discovery** — verified (method)
  - Quote: "transforming its generative AI models and algorithms into a next-generation AI platform, expediting the discovery and delivery of novel therapies and medicines to people"

- **Lab in a loop accelerates iterative therapy development** — verified (method)
  - Quote: "extensive experimental data feeds computational models that uncover patterns and make new, experimentally testable predictions. Scientists quickly assess these predictions in the lab"

- **AI improves drug development predictability and cost-effectiveness** — verified (method)
  - Quote: "AI plays an invaluable role in revolutionizing drug development, in combination with people, science and technology, helping make it more predictable and cost-effective, boosting the success rate of R..."

- **AI enables selection of most promising cancer vaccine neoantigens** — verified (method)
  - Quote: "By using AI approaches, we can select the most promising neoantigens (proteins generated by tumour-specific mutations) for cancer vaccines, hopefully leading to more effective treatments for individua..."

- **AI enables rapid generation and testing of thousands of virtual molecular structures** — verified (method)
  - Quote: "AI and ML also enable the rapid generation and testing of virtual structures for thousands of new molecules and the simulation of their interactions with therapeutic targets"

- **AI strategies optimize antibody design and predict small-molecule activity** — verified (method)
  - Quote: "AI strategies are being deployed to optimise antibody design, predict small-molecule activity, identify new antibiotic compounds and explore new disease indications for investigational therapies"

## Sources

- **S1**: https://www.gene.com/media/press-releases/15010/2023-11-21/genentech-and-nvidia-enter-into-strategi
- **S2**: https://www.roche.com/stories/ai-revolutionising-drug-discovery-and-transforming-patient-care
- **S3**: https://www.drugpatentwatch.com/blog/the-ai-revolution-in-drug-repurposing-a-comprehensive-pipeline-analysis-from-target-identification-to-clinical-and-commercial-validation/
- **S4**: https://www.gobeyond.ai/ai-resources/case-studies/roche-ai-ml-drug-discovery-development
